share_log

Cocrystal Pharma Plans To Extend Phase 2a Influenza Challenge Study With Oral PB2 Inhibitor CC-42344 Due To Low Influenza Infection Among Challenged Participants

Benzinga ·  Dec 31, 2024 21:03

"While CC-42344 showed a favorable safety and tolerability profile, we're disappointed by the low infectivity rate of the challenge influenza strain used in this study. The establishment of robust influenza infection in healthy, uninfected study subjects is critical to determine clinical endpoints for evaluating antiviral molecules. The low infectivity obtained in this study hindered antiviral data analysis," said Sam Lee, Ph.D., Cocrystal's President and co-CEO.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment